Events
-
2025/03/27 Correctseq
Precise and Efficient RNA Editing by Cleaving ADAR Inhibitor
Recently, a collaborative team led by Professor Chen Jia from the School of Life Science and Technology (SLST) at ShanghaiTech University and Professor Yang Li at Fudan University published a study titled “Specific and Efficient RNA A-to-I Editing through Cleavage of an ADAR Inhibitor”in Nature Biotechnology.
-
2025/03/27 Correctseq
An Efficient and Precise Mitochondrial Adenine Base Editor
Mitochondria, the “powerhouses” of cells, play a vital role in adenosine triphosphate (ATP) production. Mitochondria possess their own independent DNA, termed mitochondrial DNA (mtDNA), which encodes
-
2025/03/19 Correctseq
CorrectSequence Therapeutics’ CS-101 Successfully Treats Malaysian β-Thalassemia Patient
CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced its self-developed base editing therapy, CS-101, has achieved another major milestone in the treatment of β-thalassemia. In collaboration with the First Affiliated Hospital of Guangxi Medical University, CS-101 has successfully treated the second overseas patient—a Malaysian individual with transfusion-dependent β-thalassemia. This milestone follows the first cure of a β-thalassemia overseas patient from Laos, marking another significant global achievement for the company
-
2024/12/10 SHINE
Locally-Developed Gene Editing Technology Cures Boy with Serious Blood Disorder
A 14-year-old boy with serious thalassemia has recovered due to a locally-developed innovative gene editing technology, the Children's Hospital of Fudan University said on Monday.
-
2024/12/05 Correctseq
CorrectSequence Therapeutics to Participate in the 66th ASH Annual Meeting and Exposition
Dec 5, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announc
-
2024/07/22 Correctseq
The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China
On July 20, 2024, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent β-thalassemia. U
-
2024/07/19 Correctseq
CS-101 Clinical Result Included in EHA2024 Scientific Congress Report
Recently, the European Hematology Association (EHA) released the EHA2024 Scientific Congress Report titled "EHA Perspectives on Emerging Technologies in Hematology". As the world's firs
-
2024/06/06 Correctseq
CorrectSequence Therapeutics to Participate in EHA2024 Hybrid Congress
June 6, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ